10-QPeriod: Q2 FY2023

BeOne Medicines Ltd. Quarterly Report for Q2 Ended Jun 30, 2023

Filed August 2, 2023For Securities:ONCBEIGF

Summary

BeiGene, Ltd. (ONC) reported its second quarter 2023 financial results, showcasing significant revenue growth driven by strong performance in its key products, BRUKINSA and tislelizumab. Total revenues surged by 74.3% year-over-year, reaching $595.3 million, primarily due to an 81.8% increase in product revenue to $553.7 million. This growth was fueled by substantial increases in BRUKINSA sales, particularly in the U.S. and Europe, and continued strong sales of tislelizumab in China. Collaboration revenue also saw a modest increase of 12.0%. Despite the top-line growth, the company's operating expenses increased by 17.0%, leading to a continued net loss of $381.1 million for the quarter. However, the net loss narrowed by 32.6% compared to the same period last year, reflecting the significant revenue growth. The company ended the quarter with a strong cash position of $3.4 billion, providing a substantial runway for continued investment in its pipeline and operations.

Financial Highlights

53 data points
Beta

Revenue

$595.26M

83.9% Gross Margin

Net Income

-$381.14M

-64.0% Net Margin

EPS (Diluted)

$-0.28

Total Assets

$5.73B

Cash & Equivalents

$3.42B

Free Cash Flow

-$415.36M

Financial Statements
Beta
Revenue$595.26M
Cost of Revenue$95.99M
Gross Profit$499.27M
R&D Expenses$422.76M
SG&A Expenses$395.03M
Operating Expenses$817.99M
Operating Income-$318.71M
Interest Expense$4.89M
Net Income-$381.14M
EPS (Basic)$-0.28
EPS (Diluted)$-0.28
Shares Outstanding (Basic)1.36B
Shares Outstanding (Diluted)1.36B

Key Highlights

  • 1Total revenues increased significantly by 74.3% to $595.3 million for Q2 2023 compared to $341.6 million in Q2 2022.
  • 2Product revenue grew by 81.8% to $553.7 million, driven by strong sales of BRUKINSA and tislelizumab.
  • 3BRUKINSA sales demonstrated exceptional growth, increasing by 139.4% to $308.3 million globally in Q2 2023.
  • 4Tislelizumab sales in China also showed robust growth of 42.5%, reaching $149.5 million in Q2 2023.
  • 5Operating expenses increased by 17.0% to $914.0 million, primarily due to higher R&D and SG&A costs.
  • 6The net loss for Q2 2023 was $381.1 million, a 32.6% improvement compared to a net loss of $565.7 million in Q2 2022.
  • 7The company ended the quarter with $3.4 billion in cash, cash equivalents, and restricted cash, indicating a strong liquidity position.

Frequently Asked Questions

The primary driver of BeiGene's revenue growth was the significant increase in product revenue, which grew by 81.8% year-over-year to $553.7 million. This was largely due to strong global sales of BRUKINSA and continued robust sales of tislelizumab.

BeiGene reported a net loss of $381.1 million for Q2 2023, which represents an improvement of 32.6% compared to the net loss of $565.7 million in Q2 2022. This improvement was driven by substantial revenue growth, which outpaced the increase in operating expenses.

BeiGene ended Q2 2023 with a strong cash, cash equivalents, and restricted cash balance of $3.4 billion. This substantial liquidity provides the company with a solid financial footing to fund its ongoing research and development activities, clinical trials, commercialization efforts, and other operational needs for at least the next 12 months.

Yes, several key developments were noted. These include regaining full global rights to ociperlimab from Novartis, FDA acceptance of a supplemental new drug application for BRUKINSA for follicular lymphoma, a positive opinion for tislelizumab's approval in Europe for esophageal squamous cell carcinoma, and an agreement for BeiGene to acquire an option for a global license to a DualityBio ADC therapy.